Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vivoryon Therapeutics AG (GB:0R3M)
LSE:0R3M
RESEARCH TOOLSreports
Vivoryon Therapeutics AG (0R3M) Share Price & Analysis
1 Followers
0R3M Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.41 - €19.40
Previous Close€0.8
Volume24.73K
Average Volume (3M)6.38K
Market Cap
€20.71M
Enterprise Value-€3.50M
Total Cash (Recent Filing)€24.39M
Total Debt (Recent Filing)€179.00K
Price to Earnings (P/E)-0.7
Beta2.51
Next Earnings
Jun 12, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares OutstandingN/A
10 Day Avg. Volume3,014
30 Day Avg. Volume6,379
Standard Deviation0.40
R-Squared0.04
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.70Price Target Upside-12.39% Downside
Rating ConsensusHold
Number of Analyst Covering1
Options Prices
Currently, No data available
---
Ownership Overview
1.79% Insiders
0.46% Mutual Funds
0.00% Other Institutional Investors
97.75% Public Companies and
Individual Investors
0R3M FAQ
What was Vivoryon Therapeutics AG’s price range in the past 12 months?
Vivoryon Therapeutics AG lowest share price was €0.41 and its highest was €19.40 in the past 12 months.
What is Vivoryon Therapeutics AG’s market cap?
Currently, no data Available
When is Vivoryon Therapeutics AG’s upcoming earnings report date?
Vivoryon Therapeutics AG’s upcoming earnings report date is Jun 12, 2024 which is in 45 days.
How were Vivoryon Therapeutics AG’s earnings last quarter?
Vivoryon Therapeutics AG released its earnings results on Apr 24, 2024. The company reported -€0.676 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.676.
Is Vivoryon Therapeutics AG overvalued?
According to Wall Street analysts Vivoryon Therapeutics AG’s price is currently Overvalued.
Does Vivoryon Therapeutics AG pay dividends?
Vivoryon Therapeutics AG does not currently pay dividends.
What is Vivoryon Therapeutics AG’s EPS estimate?
Vivoryon Therapeutics AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivoryon Therapeutics AG have?
Vivoryon Therapeutics AG has 25,890,993 shares outstanding.
What happened to Vivoryon Therapeutics AG’s price movement after its last earnings report?
Vivoryon Therapeutics AG reported an EPS of -€0.676 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 19.444%.
Which hedge fund is a major shareholder of Vivoryon Therapeutics AG?
Currently, no hedge funds are holding shares in GB:0R3M
---
Vivoryon Therapeutics AG Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€0.70 (-12.39% Downside)
€0.70 (-12.39% Downside)
Insider Transactions
Sold Shares
Worth €7.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-94.02%
12-Months-Change
Fundamentals
Return on Equity
-107.38%
Trailing 12-Months
Asset Growth
-1.75%
Trailing 12-Months
Company Description
Vivoryon Therapeutics AG
Vivoryon Therapeutics AG is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products includes PQ912, PQ1565 and PQ-family.
---
0R3M Stock 12 Months Forecast
Average Price Target
€0.70
▼(-12.39% Downside)
Technical Analysis
Best Analysts Covering 0R3M
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-95.50%
reiterated a buy rating 11 months ago
Copying Christian Ehmann's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -95.50% per trade.
---